✦ LIBER ✦

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

✍ Scribed by Douillard, J. Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocakova, I.; Ruff, P.; B asi ska-Morawiec, M.; makal, M.; Canon, J. L.; Rother, M.; Oliner, K. S.; Tian, Y.; Xu, F.; Sidhu, R.

Book ID: 121733398
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 576 KB
Volume: 25
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu141

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final results from a randomized phase 3

Final results from a randomized phase 3 study of FOLFIRI panitumumab for second-line treatment of metastatic colorectal cancer

✍ Peeters, M.; Price, T. J.; Cervantes, A.; Sobrero, A. F.; Ducreux, M.; Hotko, Y. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 350 KB

10LBA Randomized phase 3 study of panitu

10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial

✍ J. Douillard; S. Siena; J. Cassidy; J. Tabernero; R. Burkes; M.E. Barugel; Y. Hu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A comparison of XELOX with FOLFOX-4 as f

A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

✍ Grothey, Axel 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB

6095 POSTER Randomized, Open-label, Phas

6095 POSTER Randomized, Open-label, Phase 3 Study of Panitumumab (Pmab) With FOLFOX4 Vs FOLFOX4 Alone as 1st-line Treatment for Metastatic Colorectal Cancer (mCRC) – the Role of Hypomagnesemia (Hypomag) on Efficacy

✍ Burkes, R.; Siena, S.; Cassidy, J.; Tabernero, J.; Barugel, M.E.; Humblet, Y.; C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase III Trial of FOLFOX plus Bevacizum

Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III

✍ Jane D. Robertson; Nick A. Botwood; Mace L. Rothenberg; Hans-Joachim Schmoll 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 77 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB